

Registration No. 333-181358  
Registration No. 333-190891  
Registration No. 333-204560  
Registration No. 333-219881  
Registration No. 333-221531  
Registration No. 333-227179  
Registration No. 333-227180  
Registration No. 333-228445  
Registration No. 333-231551

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-181358  
POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-190891  
POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-204560  
POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-219881  
POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-221531  
POST-EFFECTIVE AMENDMENT NO. 2 to FORM S-8 REGISTRATION STATEMENT NO. 333-227179  
POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-227180  
POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-228445  
POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-8 REGISTRATION STATEMENT NO. 333-231551

*UNDER*  
*THE SECURITIES ACT OF 1933*

**MELINTA THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

45-4440364

(I.R.S. Employer Identification Number)

44 Whippany Road  
Morristown, NJ 07960  
(908) 617-1309

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

Peter J. Milligan  
Chief Financial Officer  
Melinta Therapeutics, Inc.

44 Whippany Road  
Morristown, NJ 07960  
(908) 617-1309

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

Cempra, Inc. 2011 Equity Incentive Plan  
Cempra, Inc. Sixth Amended and Restated 2006 Stock Plan  
2011 Equity Incentive Plan, as amended  
Melinta Therapeutics, Inc. 2011 Equity Incentive Plan  
Employment Inducement Grants for Daniel Mark Wechsler  
Melinta Therapeutics, Inc. 2018 Stock Incentive Plan  
Employment Inducement Grant for Peter J. Milligan  
Employment Inducement Stock Option Grant for Timothy Simon  
Employment Inducement Restricted Stock Unit Grant for Timothy Simon

(Full title of the plans)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input checked="" type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

## EXPLANATORY NOTE

### DEREGISTRATION OF SECURITIES

This Post-Effective Amendment (this “Amendment”) relates to the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) filed by Melinta Therapeutics, Inc., a Delaware corporation (the “Company”) with the Securities and Exchange Commission (the “SEC”):

- Registration Statement on Form S-8 (No. 333-181358), filed with the SEC on May 11, 2012;
- Registration Statement on Form S-8 (No. 333-190891), filed with the SEC on August 29, 2013;
- Registration Statement on Form S-8 (No. 333-204560), filed with the SEC on May 29, 2015;
- Registration Statement on Form S-8 (No. 333-219881), filed with the SEC on August 10, 2017;
- Registration Statement on Form S-8 (No. 333-221531), filed with the SEC on November 13, 2017;
- Registration Statement on Form S-8 (No. 333-227179), filed with the SEC on September 4, 2018, as amended by Post-Effective Amendment No. 1 on November 16, 2018;
- Registration Statement on Form S-8 (No. 333-227180), filed with the SEC on September 4, 2018;
- Registration Statement on Form S-8 (No. 333-228445), filed with the SEC on November 16, 2018; and
- Registration Statement on Form S-8 (No. 333-231551), filed with the SEC on May 16, 2019.

The purpose of this Amendment is to deregister all remaining securities available for issuance under the Registration Statements.

On April 20, 2020, the Company's Modified Amended Joint Chapter 11 Plan of Reorganization of Melinta Therapeutics, Inc. and its debtors affiliates, dated March 31, 2020, under chapter 11 of Title 11 of the United States Code, as confirmed by the United States Bankruptcy Court for the District of Delaware on April 11, 2020, became effective and all outstanding securities of the Company were cancelled. Accordingly, the Company is filing this Amendment to remove from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Morristown, State of New Jersey, on this April 20, 2020. No other person is required to sign this Amendment to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

**MELINTA THERAPEUTICS, INC.**

By: /s/ Peter J. Milligan  
Name: Peter J. Milligan  
Title: Chief Financial Officer